10-Q: Precision BioSciences Reports Q2 Loss Amid Pipeline Progress

Precision BioSciences reported a significant net loss in Q2 2025 due to reduced collaboration revenue, while highlighting positive clinical and preclinical data for its gene editing programs and extending its cash runway.

Summary

• Precision BioSciences reported a net loss of $23.5 million for the three months ended June 30, 2025, a significant decline from a net income of $32.7 million in the same period of 2024.
• Revenue for Q2 2025 was less than $0.1 million, down from $49.9 million in Q2 2024, primarily due to the conclusion of the Prevail Therapeutics Agreement in April 2024.
• For the six months ended June 30, 2025, the net loss was $44.1 million, compared to a net income of $41.3 million for the same period in 2024.
• Research and development expenses decreased to $12.8 million in Q2 2025 from $17.2 million in Q2 2024, driven by lower manufacturing and toxicology costs for PBGENE-HBV and the pausing of PBGENE-3243, partially offset by increased investment in PBGENE-DMD.
• General and administrative expenses increased to $9.1 million in Q2 2025 from $8.5 million in Q2 2024.
• Cash and cash equivalents stood at $62.2 million as of June 30, 2025, down from $85.9 million at December 31, 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, was $39.3 million, an increase from $33.9 million in the prior year period.
• The company has extended its expected cash runway into the second half of 2027, supported by existing cash, operational receipts, and operational efficiencies.
• Phase 1 safety and efficacy data for Cohort 1 of the ELIMINATE-B trial (PBGENE-HBV) showed the treatment was well-tolerated with substantial HBsAg reductions (56%, 69%, 47%) in all three patients.
• Preclinical data for PBGENE-DMD demonstrated significant, durable functional improvement in a humanized DMD mouse model, with up to 85% dystrophin-positive cells in the gastrocnemius.
• The Data Monitoring Committee recommended initiating Cohort 3 for PBGENE-HBV based on favorable safety profiles in Cohorts 1 and 2.
• PBGENE-DMD received Rare Pediatric Disease designation in June 2025 and Orphan Drug Designation in July 2025 from the FDA.
• iECURE reported a complete clinical response in the first patient dosed for neonatal onset OTC deficiency, with a second infant dosed in H1 2025.
• Imugene, a partner, reported an overall response rate of 75% and a Complete Response rate of 55% for azer-cel in DLBCL, and expects to request an end of Phase 1 meeting with the FDA in Q4 2025.

Sentiment

Score: 4

Explanation: The financial results show a significant deterioration with a large net loss and revenue decline, and increased cash burn. However, the company has extended its cash runway and reported promising early clinical and preclinical data for its core gene editing programs and partner assets, which provides some positive counterbalance to the negative financial performance.

Positives

• PBGENE-HBV Phase 1 Cohort 1 data showed the treatment was well-tolerated with no serious adverse events or dose-limiting toxicities, and demonstrated substantial HBsAg reductions (56%, 69%, 47%) in all three patients.
• One patient in PBGENE-HBV Cohort 1 achieved a durable HBsAg reduction of approximately 50% from baseline, maintained for seven months after initial dosing, indicating potential for a durable antiviral response.
• Initial safety data from PBGENE-HBV Cohort 2 (0.4 mg/kg) showed no adverse events above Grade 2, no serious adverse events, and no cumulative adverse effects, leading to Data Monitoring Committee recommendation for Cohort 3 initiation.
• PBGENE-DMD preclinical data demonstrated the ability to target key muscle types and showed significant, durable functional improvement in a humanized DMD mouse model.
• PBGENE-DMD achieved a three-fold increase in dystrophin-positive muscle cells between three and nine months in quadricep, gastrocnemius, heart, and diaphragm, with up to 85% positive cells in the gastrocnemius.
• PBGENE-DMD received FDA Rare Pediatric Disease designation in June 2025 and Orphan Drug Designation in July 2025, highlighting unmet medical need.
• iECURE, a collaboration partner, reported a complete clinical response in the first patient dosed for neonatal onset OTC deficiency, with the patient now over one year old and tolerating appropriate protein levels.
• Imugene, another partner, reported improved clinical data for azer-cel in DLBCL, with the best overall response rate reaching 75% and the Complete Response rate reaching 55%.
• Imugene's azer-cel received FDA Fast Track Designation for DLBCL, indicating potential for expedited development and review.
• The company has extended its cash runway into the second half of 2027, providing more time for clinical data readouts for key programs.
• Initiated operating efficiencies in July 2025, including expense reductions in early research, manufacturing, and general and administrative, to reduce annual operating expenses.

Negatives

• Revenue for the three months ended June 30, 2025, was less than $0.1 million, a drastic decrease from $49.9 million in the prior year, primarily due to the conclusion of the Prevail Therapeutics Agreement.
• The company reported a net loss of $23.5 million for Q2 2025, a significant shift from a net income of $32.7 million in Q2 2024.
• The accumulated deficit increased to $526.5 million as of June 30, 2025, from $482.5 million at December 31, 2024, indicating continued unprofitability.
• Net cash used in operating activities increased to $39.3 million for the six months ended June 30, 2025, from $33.9 million in the prior year, reflecting an increased cash burn.
• Net cash provided by financing activities decreased significantly to $16.0 million for the six months ended June 30, 2025, from $40.8 million in the prior year, indicating reduced access to capital compared to the previous period.
• Development of PBGENE-3243 for m.3243 associated mitochondrial disease has been paused to prioritize other lead programs.
• The company is subject to the 'Baby Shelf Rule,' limiting its ability to raise capital through primary public offerings via Form S-3 to one-third of its public float until the public float exceeds $75 million.

Risks

• Incurred significant operating losses since inception and expect to continue incurring losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• Will need substantial additional funding, and inability to raise sufficient capital on acceptable terms may force delays, reductions, or elimination of research programs, product development, and commercialization efforts.
• Limited operating history makes it difficult to evaluate current business and future prospects, increasing investment risk.
• ARCUS is a novel technology, making it difficult to predict the time, cost, and potential success of product candidate development, with limited human safety and efficacy data available.
• Heavy dependence on the successful development and translation of ARCUS, with no assurance that product candidates will be successfully developed and commercialized.
• Adverse public perception of genome editing may negatively impact developmental progress or commercial success.
• Significant competition in industries experiencing rapid technological change, with competitors potentially achieving regulatory approval or developing safer/more effective treatments sooner.
• Future profitability depends on the ability to commercialize products globally, which subjects the company to various international risks and uncertainties.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• The regulatory landscape for therapeutic product candidates is rigorous, complex, uncertain, and subject to change, potentially causing delays or termination of development or unexpected costs.
• Clinical trials are difficult to design and implement, expensive, time-consuming, and involve uncertain outcomes, with inability to successfully and timely conduct them substantially harming the business.
• Product candidates may be novel, complex, and difficult to manufacture, with manufacturing problems potentially leading to development and commercialization delays.
• Even if regulatory approval is obtained, products remain subject to ongoing regulatory requirements, resulting in significant additional expense.
• Approved products may fail to achieve sufficient market acceptance by physicians, patients, and payors.
• Future success depends on key executives and the ability to attract, retain, and motivate qualified personnel.
• Failure to meet Nasdaq Capital Market listing requirements could result in delisting of common stock.
• Subject to increased costs and management demands as a public company, particularly after no longer qualifying as an emerging growth company.
• Information technology system failures, cyberattacks, or cybersecurity deficiencies could adversely affect business and operations.
• Insurance policies are expensive and may not cover all business risks, leaving significant uninsured liabilities.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or significant costs.
• Business operations may expose the company to penalties for potential misconduct or improper activity.
• Complex tax rules and potential audits, investigations, or tax proceedings could have a material adverse effect.
• May not be able to utilize all, or any, of net operating loss carryforwards due to limitations like Section 382 of the Code.
• Reliance on third parties for certain research, development, and commercialization activities, with risks if collaborations are unsuccessful.
• Inability to establish collaborations on commercially reasonable terms may alter research, development, and commercialization plans.
• Reliance on third parties to conduct, supervise, and monitor clinical trials and preclinical testing, with risks if they do not perform satisfactorily.
• Reliance on third parties for raw materials and manufacturing, with risks of supply interruptions or quality issues.
• Inadequate protection of proprietary rights or inability to enforce them could decline competitive position.
• Third parties may assert claims alleging infringement of their patents and proprietary rights, or the company may need to defend/enforce its patents, leading to substantial costs or delays.
• Developments in patent law could negatively impact the business.
• Inability to protect the confidentiality of trade secrets and enforce intellectual property assignment agreements would harm business and competitive position.
• Will not seek to protect intellectual property rights in all jurisdictions, and may not adequately enforce them where protection is sought.
• May not be successful in obtaining or maintaining necessary rights to product components and processes for the development pipeline through acquisitions and in-licenses.
• If trademarks and trade names are not adequately protected, name recognition may not be built.
• Could be subject to securities class action litigation.
• Do not currently intend to pay dividends on common stock.
• Provisions in corporate documents or Delaware law might discourage, delay, or prevent a change in control or management.
• Reduced disclosure requirements as a smaller reporting company may make common stock less attractive to investors.
• Adverse or misleading opinions from securities or industry analysts could cause stock price and trading volume to decline.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and stock price.

Future Outlook

The company is solely focused on developing in vivo gene editing therapies using its ARCUS platform, with PBGENE-HBV and PBGENE-DMD as lead programs. It expects to complete dosing for PBGENE-HBV Cohort 2 and commence Cohort 3, with a data update anticipated later in 2025. For PBGENE-DMD, the company is advancing IND-enabling toxicology studies with an anticipated IND/CTA filing by the end of 2025 and initial clinical data expected in 2026. The company has extended its cash runway into the second half of 2027, which is expected to be sufficient to enable potential commencement of a Phase 2 study for PBGENE-HBV and a potential pivotal study for PBGENE-DMD, pending supportive Phase 1 data. Operating efficiencies, including expense reductions, were initiated in July 2025 to support this runway extension. The company also anticipates continued progress from its collaborations with iECURE and Imugene, with iECURE expecting to complete OTC-HOPE enrollment in 2025 and provide complete data in H1 2026, and Imugene planning an end of Phase 1 meeting with the FDA in Q4 2025 for azer-cel.

Management Comments

• We are on track to complete dosing of all three patients across all dose administrations in Cohort 2 and commence dosing Cohort 3 for PBGENE-HBV.
• We expect to provide a data update later in 2025 for PBGENE-HBV.
• We are advancing the final U.S. investigational new drug (IND)-enabling toxicology studies with an anticipated IND and/or clinical trial application (CTA) filing targeted by the end of 2025 with initial clinical data expected in 2026 for PBGENE-DMD.
• We have also extended our expected cash runway to the second half of 2027 to enable meaningful clinical data readouts for both programs (PBGENE-HBV and PBGENE-DMD).
• In July 2025, we initiated an operating efficiency program, including reductions in early research, manufacturing, and general and administrative operating expenses, which are aimed at reducing our annual operating expenses.

Industry Context

Precision BioSciences operates in the rapidly evolving gene editing and biopharmaceutical fields, focusing on in vivo gene editing. The industry is characterized by high R&D costs, long development timelines, and significant competition from companies utilizing various gene editing technologies (e.g., CRISPR/Cas9, zinc finger nucleases, TALENs) and traditional therapies. The company's strategic shift to solely in vivo gene editing reflects a trend towards specialized focus in the biotech sector. Positive early clinical data for gene editing therapies, such as those from Precision's PBGENE-HBV and partner iECURE's OTC program, contribute to the growing validation of gene editing as a therapeutic modality. The FDA's designations (Rare Pediatric Disease, Orphan Drug, Fast Track) for the company's and its partners' programs underscore the high unmet medical need in these areas and the regulatory support for innovative treatments. However, the industry also faces increasing scrutiny on drug pricing and reimbursement, as evidenced by the Inflation Reduction Act, which could impact future commercialization.

Comparison to Industry Standards

• PBGENE-HBV's approach to eliminate cccDNA and inactivate integrated HBV DNA directly targets the root cause of chronic Hepatitis B, differentiating it from existing antiviral therapies that primarily suppress viral replication. Comparable companies developing HBV cures include Gilead Sciences (various antiviral agents), Arbutus Biopharma (RNAi therapeutics), and Vir Biotechnology (siRNA and monoclonal antibodies), though few have advanced gene editing approaches to this stage.
• PBGENE-DMD's strategy to excise exons 45-55 to restore a near-full length dystrophin protein aims for a more functional outcome compared to synthetic, truncated dystrophin approaches. Competitors in the DMD space include Sarepta Therapeutics (exon-skipping therapies like Elevidys, Exondys 51, Vyondys 53), Pfizer (gene therapy), and Solid Biosciences (gene therapy). Precision's approach with two complementary ARCUS nucleases in a single AAV is a distinct mechanism.
• The 75% overall response rate and 55% complete response rate for Imugene's azer-cel in relapsed/refractory DLBCL are competitive within the CAR T cell therapy landscape. Approved autologous CAR T therapies for DLBCL, such as Yescarta (Gilead/Kite Pharma) and Kymriah (Novartis), have shown complete response rates in the range of 40-55% in similar patient populations in pivotal trials. Azer-cel's allogeneic nature, if successful, could offer significant advantages in terms of accessibility and manufacturing over autologous therapies.
• iECURE's complete clinical response in the first OTC deficiency patient is a promising early signal for gene insertion therapies in rare metabolic disorders. Other companies pursuing gene therapies for OTC deficiency include Ultragenyx Pharmaceutical (gene therapy) and Horizon Therapeutics (enzyme replacement therapy), but iECURE's ARCUS-mediated gene insertion offers a potentially curative approach by restoring functional protein production.

Corporate Governance

Related Party Transactions

• The company holds an investment in iECURE, Inc. (iECURE) and accounts for it under the equity method, owning approximately 22% of Elo's voting shares as of June 30, 2025. Changes in the fair value of this investment are recorded in other (expense) income.
• The company has a $10.0 million promissory note receivable from Elo, with a carrying value of $5.7 million as of June 30, 2025, which matures on the earlier of December 1, 2028, or a Deemed Liquidation Event.
• The company acts as a guarantor for Imugene's assumption of the Manufacturing Center for Advanced Therapeutics (MCAT) Lease through August 31, 2027, representing a contingent liability of approximately $3.5 million.

Stakeholder Impact

• **Shareholders**: Experienced significant dilution from past offerings and face potential future dilution from ongoing capital raises. The substantial net loss and increased cash burn negatively impact shareholder value in the short term, but positive clinical data for pipeline assets offer long-term potential.
• **Employees**: Subject to operating efficiencies and expense reductions initiated in July 2025, which include employment-related reductions. Share-based compensation remains a component of employee compensation.
• **Customers/Patients**: Potential for new therapeutic options for chronic Hepatitis B and Duchenne Muscular Dystrophy, as well as for OTC deficiency and DLBCL through collaborations, offering hope for improved health outcomes.
• **Suppliers/Creditors**: The company's reliance on third-party CMOs and CROs for manufacturing and clinical trials means their operational stability is important. The $22.5 million term loan with Banc of California and the requirement to maintain a cash security account impact the company's financial flexibility and relationship with its lender.
• **Collaboration Partners (Novartis, TG Therapeutics, iECURE, Imugene)**: Continued collaboration and potential milestone payments or royalties are dependent on the successful development and commercialization of product candidates. The strategic shift and pausing of certain programs may affect the scope of future collaborations.

Next Steps

• Complete dosing of all three patients across all dose administrations in PBGENE-HBV Cohort 2.
• Commence dosing for PBGENE-HBV Cohort 3.
• Provide a data update for PBGENE-HBV later in 2025.
• Advance final U.S. IND-enabling toxicology studies for PBGENE-DMD.
• File an IND and/or CTA for the PBGENE-DMD program by the end of 2025.
• Expect initial clinical data for PBGENE-DMD in 2026.
• iECURE expects to complete enrollment in the OTC-HOPE study in 2025.
• iECURE anticipates complete data from the OTC-HOPE trial in the first half of 2026.
• Imugene expects to request an end of Phase 1 meeting with the FDA in Q4 2025 to discuss designs for a pivotal/registrational trial for azer-cel.
• Continue to implement operating efficiencies, including employment-related and other expense reductions, to reduce annual operating expenses.

Key Dates

Recommendation

While the financial results for the quarter and year-to-date show a significant decline in revenue and increased net losses, reflecting the strategic shift and conclusion of past collaboration agreements, the underlying clinical and preclinical pipeline updates are promising. The positive early safety and efficacy data for PBGENE-HBV, the strong preclinical data and orphan designations for PBGENE-DMD, and the encouraging updates from iECURE and Imugene indicate scientific progress. The extended cash runway provides critical time for these programs to mature. However, the company faces substantial future funding needs and dilution risk due to the 'Baby Shelf Rule.' A seasoned investor would likely 'hold' to monitor the progression of the lead clinical programs (PBGENE-HBV and PBGENE-DMD) and the company's ability to secure additional non-dilutive funding or strategic partnerships, as these clinical milestones are critical for long-term value creation despite the current financial headwinds.

Keywords

Gene Editing, ARCUS, Hepatitis B, Duchenne Muscular Dystrophy, HBV, DMD, Clinical Trials, Biotechnology, Pharmaceutical, Rare Disease, Orphan Drug, Oncology, CAR T, Financial Results, SEC Filing, Biopharma